Literature DB >> 25546806

Immunoglobulins: current understanding and future directions.

S Jolles1, S C Jordan, J S Orange, I N van Schaik.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25546806      PMCID： PMC4285535          DOI： 10.1111/cei.12555

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  66 in total

1.  Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM.

Authors:  Benoit Pasquier; Pierre Launay; Yutaka Kanamaru; Ivan C Moura; Séverine Pfirsch; Claude Ruffié; Dominique Hénin; Marc Benhamou; Marina Pretolani; Ulrich Blank; Renato C Monteiro
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

2.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

Authors:  Mary Lucas; Martin Lee; Jenny Lortan; Eduardo Lopez-Granados; Siraj Misbah; Helen Chapel
Journal:  J Allergy Clin Immunol       Date:  2010-05-14       Impact factor: 10.793

3.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

4.  IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.

Authors:  Jean-Claude Bystryn; Diane Jiao
Journal:  Autoimmunity       Date:  2006-11       Impact factor: 2.815

5.  Immunoglobulin g for the treatment of chronic pain: report of an expert workshop.

Authors:  Stefano Tamburin; Kristian Borg; Xavier J Caro; Stefano Jann; Alexander J Clark; Francesca Magrinelli; Gen Sobue; Lars Werhagen; Giampietro Zanette; Haruki Koike; Peter J Späth; Angela Vincent; Andreas Goebel
Journal:  Pain Med       Date:  2014-01-14       Impact factor: 3.750

6.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

Review 7.  Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data.

Authors:  Mark Ballow
Journal:  Ann Allergy Asthma Immunol       Date:  2013-12       Impact factor: 6.347

8.  TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance.

Authors:  Kang Mi Lee; Ryan T Stott; Gaoping Zhao; Julie SooHoo; Wei Xiong; Moh Moh Lian; Lindsey Fitzgerald; Shuai Shi; Elsie Akrawi; Ji Lei; Shaoping Deng; Heidi Yeh; James F Markmann; James I Kim
Journal:  Eur J Immunol       Date:  2014-05-03       Impact factor: 5.532

9.  Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors:  M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

10.  Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Authors:  Jean-Marc Léger; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Amgad Shebl; Artur Bauhofer; Othmar Zenker; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494
View more
  5 in total

1.  Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.

Authors:  Bruno Ghirotto Nunes; Flávio Vieira Loures; Heloisa Maria Siqueira Bueno; Erica Baroni Cangussu; Ernesto Goulart; Giuliana Castello Coatti; Elia Garcia Caldini; Antonio Condino-Neto; Mayana Zatz
Journal:  Eur J Hum Genet       Date:  2017-10-27       Impact factor: 4.246

2.  IVIG regulates the survival of human but not mouse neutrophils.

Authors:  Christoph Schneider; Simone Wicki; Stefanie Graeter; Tankica M Timcheva; Christian W Keller; Isaak Quast; Danila Leontyev; Iglika K Djoumerska-Alexieva; Fabian Käsermann; Stephan M Jakob; Petya A Dimitrova; Donald R Branch; Richard D Cummings; Jan D Lünemann; Thomas Kaufmann; Hans-Uwe Simon; Stephan von Gunten
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

Review 3.  Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.

Authors:  Stephen Jolles; Mikhail A Rojavin; John-Philip Lawo; Robert Nelson; Richard L Wasserman; Michael Borte; Michael A Tortorici; Kohsuke Imai; Hirokazu Kanegane
Journal:  J Clin Immunol       Date:  2018-11-10       Impact factor: 8.317

4.  Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.

Authors:  Rajiv Mallick; Stephen Jolles; Hirokazu Kanegane; Dominique Agbor-Tarh; Mikhail Rojavin
Journal:  J Clin Immunol       Date:  2018-11-21       Impact factor: 8.317

Review 5.  Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies.

Authors:  Andrea Farini; Chiara Villa; Luana Tripodi; Mariella Legato; Yvan Torrente
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.